Business Wire

GCCA: Cement and Concrete Industry Scales Up Carbon Capture, Utilisation and Storage (CCUS) Efforts to Accelerate Decarbonisation

Share

The Clean Energy Ministerial CCUS (CEM CCUS) and the Global Cement and Concrete Association (GCCA) have today, at the first-ever Global Clean Energy Action Forum (GCEAF), announced an agreement that will help scale up the deployment of carbon capture, utilisation and storage (CCUS) throughout the cement and concrete industry, in a move to stimulate innovation, investment and increase the pace of decarbonisation efforts.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220923005359/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Major CCUS industry and government collaboration announced at Global Clean Energy Action Forum (GCEAF) in Pittsburgh, USA. Left to right: Thomas Guillot, CEO of the Global Cement and Concrete Association, Henriette Nesheim, Assistant Director General, Norwegian Ministry of Petroleum and Energy – and CEM CCUS Initiative Co-Lead from Norway, Brad Crabtree, Assistant Secretary, Fossil Energy and Carbon Management, US Department of Energy (Photo: Business Wire)

Central to the agreement will be exploring incentives, policy frameworks and finance solutions at a global level that can enable industrial-scale CCUS projects over the next ten years. The two organisations will work together to ensure the long-term deployment of CCUS, beyond 2030, via both policy and technological development.

The agreement sets out the role CCUS can have in safely and effectively delivering a net zero future and facilitates the identification and mapping of potential cement-sector CCUS projects. It will explore the transport and storage infrastructure needs involved in integrating cement CCUS projects into strategic CCUS transport and storage hubs. It will also help to foster project partnerships and lead to acceleration of projects in developing economies.

Thomas Guillot, CEO of the Global Cement and Concrete Association, said: “Cement is the vital ingredient in concrete, the world’s most-used human-made material. It is the backbone of the modern world. The industry is striving to innovate at every stage of the concrete life cycle. We see carbon capture as a vital lever for the global cement industry to achieve its ambitious goal of net-zero concrete by 2050.

“We are starting to see the first CCUS projects already emerge. We have mapped 35 projects announced and underway across the world and up to 100 additional projects are also in the pipeline among our member companies who operate all around the globe.”

Mr Guillot added: “This is good progress, but we cannot achieve our decarbonisation mission alone. CCUS is a key enabling technology, and it is a critical area for collaboration to ensure that government policy, enabling infrastructure and wider investment is in place. That is why the partnership with the Clean Energy Ministerial CCUS Initiative is so important, to help unlock and accelerate further progress and deployment.”

Henriette Nesheim, Assistant Director General, Norwegian Ministry of Petroleum and Energy – and CEM CCUS Initiative Co-Lead from Norway, said: “This is a great opportunity to work together with a vitally important industry. In Norway we are already building our first cement-CCS project in Brevik, and we look forward to sharing the experience with others.”

Brad Crabtree, Assistant Secretary, Fossil Energy and Carbon Management, US Department of Energy, said: “Reaching our ambitious climate goals requires the decarbonization of various heavy industries, including cement production. In the United States, through the support of Congress, we are currently funding projects to develop carbon capture technologies in cement and other key industrial sectors that are essential to modern life, with the aim of helping to achieve net-zero emissions economywide by 2050 and retaining and creating high-wage industrial jobs. The U.S. Government is keen to drive progress in this area, together with our partners in the CEM CCUS Initiative and the Global Cement and Concrete Association.”

To reach these objectives, both parties have agreed to the organisation of expert workshops, inclusive of CEM CCUS and GCCA members, as well as relevant stakeholders and partners including the CEM Industry Deep Decarbonisation Initiative (IDDI). Both parties will also produce joint reports and organise public events outlining progress in opportunities to implement CCUS projects at strategic hubs.

The agreement was announced at a GCCA and CEM CCUS led event at the Global Energy Action Forum, focused on the challenge and opportunity for CCUS as a major decarbonisation lever for the global cement and concrete sector. This aligns with a core pillar of the GCCA’s 2050 Net Zero Roadmap, launched last year, in which its members have committed to the deployment of at least ten industrial-scale CCUS projects by 2030.

At the event, the industry summarised the key challenges in accelerating the deployment of CCUS and outlined the enabling factors crucial to increasing its rollout to create a greener concrete future. These factors include supporting policies and financing, public procurement progress and CO2 infrastructure and storage options alongside strategic hubs.

-ends-

Notes to editors:

Speakers at the GCCA and CEM CCUS led event at the Global Energy Action Forum included:

  • Henriette Nesheim, Assistant Director General, Norwegian Ministry of Petroleum and Energy – and CEM CCUS Initiative Co-Lead from Norway
  • Dan Dorner, Head of CEM Secretariat
  • Thomas Guillot, CEO, Global Cement and Concrete Association

Panel:

  • Chris Ward, CEO, Lehigh Hanson Cement
  • Bjorn Otto Sverdrup, ExCom Chair, OGCI
  • Tareq Emtairah, Director, UNIDO
  • Brad Crabtree, Assistant Secretary, Fossil Energy and Carbon Management, US Department of Energy
  • Khalid Abuleif, Chief Climate Negotiator, Saudi Arabia
  • Moderator: Juho Lipponen, CEM CCUS

About the GCCA

Launched in January 2018, the Global Cement and Concrete Association (GCCA) is dedicated to developing and strengthening the sector’s contribution to sustainable construction. The GCCA aims to foster innovation throughout the construction value chain in collaboration with industry associations as well as architects, engineers, and innovators. The association demonstrates how concrete solutions can meet global construction challenges and sustainable development goals while showcasing responsible industrial leadership in the manufacture and use of cement and concrete. It complements and supports the work of associations at national and regional levels.

About CEM CCUS

The Clean Energy Ministerial CCUS Initiative is a group of 14 member countries who have joined forces to accelerate CCUS together. The CEM CCUS countries all develop comprehensive CCUS programmes, with the intent to decarbonise all relevant industrial sectors. The objective of the Initiative is to accelerate CCUS as a viable CO2 mitigation option, facilitate diffusions of knowledge on technologies, regulations, and policies, and lead to strategic partnerships to accelerate both near- and longer-term investment in CCUS. As an action-orientate platform, the Imitative does not perform analysis, but serves to bring government, industry and the financial and investment sectors together.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media enquiries should be directed to:
GCCA@BCW-global.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release

Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t

Qualcomm Announces Quarterly Cash Dividend17.10.2025 16:00:00 EEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye